Aspirin-Free Strategies After PCI: Still Not Out of the Twilight

Affiliations

¹ Sorbonne Université, ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address: jean-philippe.collet@aphp.fr.
² Sorbonne Université, ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France.

Free article

Editorial

Jean-Philippe Collet et al. J Am Coll Cardiol. 2019.

Free article

. 2019 Oct 22;74(16):2028-2031.

doi: 10.1016/j.jacc.2019.08.998.

¹ Sorbonne Université, ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address: jean-philippe.collet@aphp.fr.
² Sorbonne Université, ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France.

No abstract available

Keywords: drug-eluting stent; dual antiplatelet therapy; multivessel percutaneous coronary intervention; ticagrelor monotherapy.

Comment on

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI.
Takahashi K, Serruys PW, Chichareon P, Chang CC, Tomaniak M, Modolo R, Kogame N, Magro M, Chowdhary S, Eitel I, Zweiker R, Ong P, Ottesen MM, Tijssen JGP, Wykrzykowska JJ, de Winter RJ, Garg S, Stoll HP, Hamm C, Steg PG, Onuma Y, Valgimigli M, Vranckx P, Carrie D, Windecker S. Takahashi K, et al. J Am Coll Cardiol. 2019 Oct 22;74(16):2015-2027. doi: 10.1016/j.jacc.2019.08.997. J Am Coll Cardiol. 2019. PMID: 31623758 Clinical Trial.